SER — Serina Therapeutics, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1708599 ·
Last close
$1.92
Market Cap
$28.80M
52W High
$3.29
52W Low
$1.22
ADV30
85,793
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,280,000 | -6,898,000 | 27,299,000 | 24,526,000 | 9,671,000 |
| Dec 2025 | 0 | — | -6,207,000 | -3,336,000 | 6,951,000 | 3,056,000 | 6,988,000 |
| Sep 2025 | 0 | — | -6,392,000 | -4,585,000 | 12,413,000 | 8,620,000 | 10,819,000 |
| Jun 2025 | 0 | — | -5,565,000 | -6,448,000 | 8,941,000 | 6,041,000 | 7,295,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,955,000
Investing CF
$-59,000
Financing CF
$17,412,000
CapEx
$-21,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.47
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-63,500,000
Inventory
—
Receivables
$14,000
ST Investments
$1,721,000
EBIT TTM
$-18,984,000
Pretax Income TTM
$-19,197,000
Interest Exp TTM
$213,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$130,000
EBITDA
$-24,370,000
Free Cash Flow
$-7,911,750
Enterprise Value
$13,278,060
Total Cash
$24,526,000
Total Debt
$3,169,000
Shares Out
14,997,505
Trailing EPS
$-2.00
Book Value
$-0.46
ROE
-221.9%
ROA
-89.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -24,022,000 | -19,182,000 | 6,951,000 | 6,988,000 | — | -17,955,000 |
| Dec 2024 | 0 | -17,048,000 | -11,141,000 | 6,724,000 | 6,216,000 | — | -17,137,000 |
| Dec 2023 | 3,000,000 | -3,129,000 | 5,269,000 | 8,968,000 | 41,262,000 | — | -2,476,000 |
| Dec 2022 | 500,000 | -2,270,368 | -2,682,108 | 858,042 | 38,636,203 | — | -2,075,624 |
TTM Snapshot
Revenues TTM
$43,000
NetIncome TTM
$3,162,000
OpCashFlow TTM
$0
Assets (Latest)
$6,724,000
Forward EPS
$-1.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SKYE | Skye Bioscience, Inc. | $28.89M | $0.82 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $28.96M | $0.07 | — |
| GRDX | GridAI Technologies Corp. | $28.58M | $4.61 | — |
| IGC | IGC Pharma, Inc. | $28.55M | $0.29 | — |
| LSTA | LISATA THERAPEUTICS, INC. | $29.14M | $3.20 | — |
News headlines (Yahoo Finance, 1h cache)
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-14 20:20 · Yahoo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
2026-05-13 12:06 · Yahoo
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
2026-04-07 10:00 · Yahoo
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
2026-04-02 20:13 · Yahoo
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
2026-03-25 20:20 · Yahoo
Serina Therapeutics to Present at the 38th Annual Roth Conference
2026-03-24 10:00 · Yahoo
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
2026-03-18 20:10 · Yahoo
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
2026-02-24 21:05 · Yahoo
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
2026-02-19 11:00 · Yahoo
Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event
2026-02-03 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.